Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Refractory Systemic Lupus Erythematosus: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Refractory Systemic Lupus Erythematosus: 1 US clinical trial tracked, none currently recruiting.

Refractory Systemic Lupus Erythematosus is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Artiva Biotherapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition refractory-systemic-lupus-erythematosus

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Refractory Systemic Lupu (th…0%
Open-enrollment share among volume-matched conditions near Refractory Systemic Lupus Erythematosus

Refractory Systemic Lupus Erythematosus has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Refractory Systemic Lupus Erythematosus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Refractory Systemic Lupus Erythematosus is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Refractory Systemic Lupus Erythematosus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AB-101 Drug
1 trials
Rituximab Drug
1 trials
Fludarabine Drug
1 trials
Cyclophosphamide Drug
1 trials
Obinutuzumab Drug
1 trials

US sites by state

Facility locations filed on Refractory Systemic Lupus Erythematosus trials. A trial with sites in several states counts in each.

Texas 1 trials
North Carolina 1 trials
Iowa 1 trials
Florida 1 trials
California 1 trials
Arizona 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Refractory Systemic Lupus Erythematosus page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Refractory Systemic Lupus Erythematosus trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Artiva Biotherapeutics sponsors the most Refractory Systemic Lupus Erythematosus trials on record, review their full trial history before evaluating a specific study. See Artiva Biotherapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Systemic Lupus Erythematosus condition card totals 1 registered trials; most-linked intervention AB-101; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.